MDXG - MiMedx Group, Inc.

Other OTC - Other OTC Delayed Price. Currency in USD
5.77
+0.23 (+4.15%)
At close: 3:59PM EDT
Stock chart is not supported by your current browser
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Performance Outlook
  • Short Term
    2W - 6W
  • Mid Term
    6W - 9M
  • Long Term
    9M+
Previous Close5.54
Open5.54
Bid0.00 x 1000
Ask0.00 x 800
Day's Range5.50 - 5.99
52 Week Range2.95 - 7.95
Volume395,233
Avg. Volume238,184
Market Cap636.598M
Beta (5Y Monthly)1.17
PE Ratio (TTM)N/A
EPS (TTM)-0.16
Earnings DateJul 06, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire

    MiMedx Files Definitive Proxy Materials

    MARIETTA, Ga., Aug. 03, 2020 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (OTC PINK: MDXG) (“MiMedx” or “the Company”), an industry leader in advanced wound care and an emerging therapeutic biologics company, today announced that it has filed a definitive proxy statement with the U.S. Securities and Exchange Commission (“SEC”) in connection with its upcoming 2019 annual meeting of shareholders (“Annual Meeting”). The meeting is scheduled to be held on August 31, 2020 at 10:00 a.m. Eastern Time at www.virtualshareholdermeeting.com/MDXG2019. Shareholders as of the record date, 5:00 p.m. Eastern Time on July 14, 2020, are entitled to notice of, and to vote at, the Annual Meeting. In light of public health concerns regarding the coronavirus (COVID-19) outbreak, the Annual Meeting will be conducted in a virtual format only to assist in protecting the health and well-being of our shareholders, directors and employees and to provide access to our shareholders regardless of geographic location.The Company is mailing the definitive proxy statement (the “Proxy Statement”) and accompanying proxy card for the 2019 annual meeting of shareholders to its shareholders. A free copy of the Proxy Statement and other relevant documents that the Company files with the SEC may be obtained through the SEC’s website at www.sec.gov or at the Company’s website at https://mimedx.com.Contact:Hilary Dixon Investor Relations & Corporate Communications 770.651.9066 investorrelations@mimedx.com

  • GlobeNewswire

    MiMedx Adds Rohit Kashyap, Ph.D., to Leadership Team as Executive Vice President and Chief Commercial Officer

    Strategic Leader with Proven Record of Delivering Growth and Business TransformationMARIETTA, Ga., July 28, 2020 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (OTC PINK: MDXG) (“MiMedx” or “the Company”), an industry leader in advanced wound care and an emerging therapeutic biologics company, today announced the addition of Rohit Kashyap, Ph.D., as Executive Vice President and Chief Commercial Officer, effective August 3, 2020. Dr. Kashyap is an accomplished strategic leader with experience in building successful global businesses, and a consistent track record of delivering growth, transforming business portfolios and building high impact teams. He brings to MiMedx more than 20 years of medical device experience, with a proven history of performance in developing strategies for market creation and commercial models that deliver value to patients and healthcare systems. Timothy R. Wright, MiMedx Chief Executive Officer, commented, “MiMedx is a pioneer in the development of amniotic tissue technology, and our products have broad applicability across a range of applications. Our Company is now at an inflection point, with the opportunity to define the MiMedx brand, raise market awareness of the growing prevalence of chronic wounds and diseases such as diabetes, and communicate the clinical and economic value of our product portfolio. I am confident that Rohit, with his breadth of industry experience, will propel our patient-centric strategy forward as we work to drive organizational growth, market expansion and pipeline maturation.”Dr. Kashyap added, “I am honored and excited to join MiMedx and help lead the commercial efforts into the next stage of its evolution. I believe the Company is uniquely positioned for growth with differentiated products that change people’s lives and, importantly, reduce the overall economic cost of healthcare. I look forward to working with the commercial team and senior leaders to increase the awareness and adoption of our products across multiple markets.”About Rohit Kashyap, Ph.D.Rohit Kashyap, Ph.D. served as the President of Global Commercial at Acelity L.P. Inc. (formerly known as Kinetic Concepts, Inc.) since April 2019. Prior to that, Dr. Kashyap was the President of Americas, since January 2017, and President of North America, since October 2014. In these roles he led the company’s growth objectives by expanding core market leadership, identifying and developing new high-growth markets, and enhancing the overall product portfolio through the integration of additional businesses. Prior thereto, Dr. Kashyap served as Senior Vice President of Strategy and Business Development at Acelity, Inc. from 2012 to 2014, and as Senior Vice President of Corporate Development from 2007 to 2010, with responsibility for the development of global strategic planning initiatives that incorporated organic growth, licensing and strategic acquisitions. Since joining the company in 1998, Dr. Kashyap contributed in various roles within the R&D, Licensing and Acquisition, and Global Marketing groups, including as Commercial Leader for international and emerging markets.Dr. Kashyap earned his bachelor’s degree in Instrumentation and Control from the L.D. College of Engineering in Ahmedabad, India, and his master’s degree and doctorate in Biomedical Engineering from Case Western Reserve University. He also completed his MBA from the Kellogg School of Management at Northwestern University.About MiMedxMiMedx® is an industry leader in advanced wound care and an emerging therapeutic biologics company developing and distributing human placental tissue allografts with patent-protected processes for multiple sectors of healthcare. The Company processes the human placental tissue utilizing its proprietary PURION® process methodology, among other processes, to produce allografts by employing aseptic processing techniques in addition to terminal sterilization. MiMedx has supplied more than 1.9 million allografts to date. For additional information, please visit www.mimedx.com.Contact:Hilary Dixon Investor Relations & Corporate Communications 770.651.9066 investorrelations@mimedx.com

  • GlobeNewswire

    MiMedx Announces Filing of 2020 First Quarter Form 10-Q

    Company Now Caught Up in Financial Reporting First Quarter Net Sales of $61.7 million MARIETTA, Ga., July 06, 2020 -- MiMedx Group, Inc. (OTC.

  • GlobeNewswire

    MiMedx Announces Filing of 2019 Annual Report

    Annual Report on Form 10-K includes Audited Financial Results for 2019 Transition to Revenue Recognition on an “As-Shipped” Basis Reflects Improved Internal Control Environment.

  • GlobeNewswire

    MiMedx Announces Concurrent $150 Million Private Equity and Debt Financings

    MiMedx Group, Inc. (OTC PINK: MDXG) (“MiMedx” or “the Company”), an industry leader in advanced wound care and an emerging therapeutic biologics company, today announced the closing of concurrent $150 million private equity and debt financings, consisting of an equity financing pursuant to a Securities Purchase Agreement with an entity controlled by EW Healthcare Partners and certain funds managed by Hayfin Capital Management LLP (“Hayfin”), and a debt financing pursuant to a Loan Agreement with Hayfin. As part of the transaction, EW Healthcare Partners has designated Martin P. Sutter and William A. Hawkins III to serve on the Company’s board as preferred directors.

  • Republican lawmakers criticize Democrats for telling 5 public companies to return small-business loans
    MarketWatch

    Republican lawmakers criticize Democrats for telling 5 public companies to return small-business loans

    Republican members of a new watchdog panel on Wednesday push back against their Democratic colleagues’ demand that five public companies return emergency loans meant for small businesses hurt by the coronavirus crisis.

  • Congressional committee demands these 5 public companies return coronavirus loans meant for small businesses
    MarketWatch

    Congressional committee demands these 5 public companies return coronavirus loans meant for small businesses

    A congressional committee tasked with overseeing coronavirus stimulus funds sent letters Friday afternoon to five public companies that took out Paycheck Protection Program loans demanding they repay the funds

  • GlobeNewswire

    MiMedx Provides Update on Payment Protection Program Loan

    MiMedx Group, Inc. (OTC PINK: MDXG) (“MiMedx” or “the Company”), an industry leader in advanced wound care and an emerging therapeutic biologics company, today announced that it is repaying the Payment Protection Program (PPP) Loan received through its application to the Federal relief effort. As announced previously, the funds enabled the Company to maintain full employment during a time of widespread uncertainty, producing skin-graft products for patients with serious wounds and burns. Similar to other companies, including those operating in the health care sector, the Company’s business has been negatively impacted by the COVID-19 pandemic.

  • GlobeNewswire

    MiMedx Announces Appointment of William L. Phelan as Chief Accounting Officer

    MiMedx Group, Inc. (OTC PINK: MDXG) (“MiMedx” or “the Company”), an industry leader in advanced wound care and an emerging therapeutic biologics company, today announced the appointment of William L. Phelan as Senior Vice President and Chief Accounting Officer, effective May 1, 2020. Mr. Phelan is a highly accomplished accounting professional with more than 25 years of experience building, leading and advising companies, and brings strong knowledge of financial reporting requirements and internal controls to the Company’s financial management team.

  • GlobeNewswire

    MiMedx Announces Additional Access to Capital and Financing

    MiMedx Group, Inc. (OTC PINK: MDXG) (“MiMedx” or “the Company”), an industry leader in advanced wound care and an emerging therapeutic biologics company, today announced that it has received notice from Bank of America that its application for a Paycheck Protection Program loan (a “PPP Loan”) under the CARES Act has been approved. The Company expects to receive the funds from the PPP Loan by the end of the month. In addition, the Company has agreed to terms for an amendment to its Loan Agreement, dated as of June 10, 2019, with Blue Torch Finance LLC (“Blue Torch”), to modify certain covenant terms in the original Term Loan Facility.

  • GlobeNewswire

    MiMedx Announces Settlement of VA Pricing Investigation

    MiMedx Group, Inc. (OTC PINK: MDXG) (“MiMedx” or the “Company”), an industry leader in advanced wound care and an emerging therapeutic biologics company, today announced that it has finalized a settlement with the Department of Justice (the “DOJ”), resolving an investigation concerning the accuracy of commercial pricing disclosures to the United States Department of Veterans Affairs (the “VA”) for one of the Company’s products in connection with the Company’s Federal Supply Schedule contract, and a related qui tam action filed in Minnesota. The Company self-disclosed the matter to the VA Office of Inspector General (VA-OIG) in November 2018, prior to its knowledge of the qui tam suit or any underlying government investigation and, as DOJ acknowledged in the settlement agreement, the Company cooperated with the government’s investigation into the matter.

  • MiMedx Names Peter M. Carlson as Chief Financial Officer
    PR Newswire

    MiMedx Names Peter M. Carlson as Chief Financial Officer

    MiMedx Group, Inc. (OTC PINK: MDXG) ("MiMedx" or "the Company"), an industry leader in advanced wound care and an emerging therapeutic biologics company, today announced that Peter M. Carlson, Executive Vice President of Finance, has been named as the Company's Chief Financial Officer, effective immediately.

  • MiMedx Announces Filing of 2018 Annual Report
    PR Newswire

    MiMedx Announces Filing of 2018 Annual Report

    MiMedx Group, Inc. (OTC PINK: MDXG) ("MiMedx" or "the Company"), an industry leader in advanced wound care and an emerging therapeutic biologics company, today announced the filing of its 2018 Annual Report, which includes the Company's audited consolidated statements of operations, and stockholders' equity and cash flows for the years ended December 31, 2018 and 2017, which the Company did not previously file, and for the year ended December 31, 2016, which the Company has restated.

  • GuruFocus.com

    Baillie Gifford Takes Aim at Stock Lending and Short Sellers

    The asset manager is unconvinced of its value to price discovery Continue reading...

  • MiMedx Announces Addition of Peter M. Carlson
    PR Newswire

    MiMedx Announces Addition of Peter M. Carlson

    MiMedx Group, Inc. (OTC PINK: MDXG) ("MiMedx" or "the Company"), an industry leader in advanced wound care and an emerging therapeutic biologics company, today announced the addition of Peter M. Carlson as Executive Vice President, Finance, effective December 16, 2019. Mr. Carlson brings more than thirty years of comprehensive financial expertise having held positions as a Fortune 50 principal accounting officer and Big Five audit partner, as well as a senior Finance executive. He will be assisting the Company in the transition of financial duties with the departure of former Interim Chief Financial Officer, Edward J. Borkowski.

  • MiMedx Provides Update Regarding Timing of Restatement
    PR Newswire

    MiMedx Provides Update Regarding Timing of Restatement

    MiMedx Group, Inc. (OTC PINK: MDXG) ("MiMedx" or the "Company"), an industry leader in advanced wound care and an emerging therapeutic biologics company, today announced that it expects to file its annual report on Form 10-K for the years ended December 31, 2018, 2017 and 2016 in early 2020.

  • Reuters

    UPDATE 1-Ex-CEO, COO of biotech firm MiMedx charged with securities fraud

    Two former executives of biotech company MiMedx Group Inc were criminally charged on Tuesday with fraudulently inflating the company's revenue. Former MiMedx Chief Executive Parker Petit and former Chief Operating Officer William Taylor were charged with securities fraud and conspiracy in an indictment in Manhattan federal court. "Pete Petit adamantly denies the charges leveled against him today, and he will vigorously defend himself in court," Petit' s lawyer, Eric Bruce, said in a statement.

  • Reuters

    Ex-CEO, COO of biotech firm MiMedx charged with securities fraud

    Two former executives of biotech company MiMedx Group Inc <MDXG.PK> were criminally charged on Tuesday with fraudulently inflating the company's revenue. Former MiMedx Chief Executive Parker Petit and former Chief Operating Officer William Taylor were charged with securities fraud and conspiracy in an indictment in Manhattan federal court. "Pete Petit adamantly denies the charges leveled against him today, and he will vigorously defend himself in court," Petit' s lawyer, Eric Bruce, said in a statement.

  • MiMedx Announces Securities and Exchange Commission Settlement
    PR Newswire

    MiMedx Announces Securities and Exchange Commission Settlement

    MiMedx Group, Inc. (OTC PINK: MDXG) ("MiMedx" or the "Company"), an industry leader in advanced wound care and an emerging therapeutic biologics company, today announced that it has finalized a settlement with the Securities and Exchange Commission (the "SEC"), resolving a previously disclosed investigation into the Company's financial accounting practices.

  • MiMedx Names William "Butch" Hulse as General Counsel and Secretary
    PR Newswire

    MiMedx Names William "Butch" Hulse as General Counsel and Secretary

    MiMedx Group, Inc. (OTC PINK: MDXG) ("MiMedx" or "the Company"), an industry leader in advanced wound care and an emerging therapeutic biologics company, today announced the addition of William "Butch" Hulse as its new General Counsel and Secretary, effective December 2, 2019. With more than twenty years' experience in large law firms and life sciences organizations, Mr. Hulse brings to MiMedx legal, risk management, compliance and operational expertise and a track record of success.

  • PR Newswire

    MiMedx Announces Resignation of Board Member

    MARIETTA, Ga., Sept. 20, 2019 /PRNewswire/ -- MiMedx Group, Inc. (OTC PINK: MDXG) ("MiMedx" or "the Company"), an industry leader in advanced wound care and an emerging therapeutic biologics company, today announced that Luis A. Aguilar has notified the Company of his resignation from the Board of Directors. Dr. Kathleen Behrens Wilsey, Chair of the MiMedx Board of Directors, stated, "On behalf of the Board and the Company, we thank Luis for his commitment and contributions.

  • PR Newswire

    MiMedx Announces Agreement Regarding 2019 and 2020 Shareholder Meetings

    MARIETTA, Ga. , Aug. 8, 2019 /PRNewswire/ -- MiMedx Group, Inc. (OTC PINK: MDXG) ("MiMedx" or the "Company"), an industry leader in advanced wound care and an emerging therapeutic biologics ...